The State Of The Art Defence: Defining the Australian Experience in the Context of Pharmaceuticals
AbstractOne of the defences within Part 3-5 of the Australian Consumer Law is the state of the art, or development risk defence. This defence, although significant, has often been neglected in Australian jurisprudential analysis and has triggered at most generic academic analysis. However, with the rise of pharmaceutical and medical device litigation in Australia, it could become a vital weapon for Australian manufacturers against product liability claims. This paper will firstly review the two ways this defence could operate. It will also discuss the three types of defects which the defence could apply to. This paper aims to determine exactly when and how this defence should apply in Australia, in the context of pharmaceutical product liability claims.
Dec 12, 2013
How to Cite
TSUI, Mabel. The State Of The Art Defence: Defining the Australian Experience in the Context of Pharmaceuticals. QUT Law Review, [S.l.], v. 13, n. 1, dec. 2013. ISSN 2201-7275. Available at: <https://lr.law.qut.edu.au/article/view/517>. Date accessed: 01 feb. 2021. doi: https://doi.org/10.5204/qutlr.v13i1.517.
Emerging Scholars' Section
Consumer law; Pharmaceuticals; Science; Technology
Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Articles in this journal are published under the Creative Commons Attribution Licence (CC-BY). This is to achieve more legal certainty about what readers can do with published articles, and thus a wider dissemination and archiving, which in turn makes publishing with this journal more valuable for authors.